Mortality Reduction with Low-Dose CT Screening for Lung Cancer
Mené auprès de 15 789 fumeurs ou anciens fumeurs âgés de 50 à 74 ans (durée minimale de suivi : 10 ans ; 2 594 femmes), cet essai évalue l'intérêt, du point de vue de la réduction de la mortalité par cancer du poumon, de plusieurs sessions de dépistage par tomographie numérique à faible dose de rayonnements
Since the publication of the first mortality results from the National Lung Screening Trial (NLST), which showed a 20% reduction in lung-cancer mortality with low-dose computed tomographic (CT) screening,1 the intervention has been adopted as policy in the United States, and there has been considerable discussion of the possibilities for its adoption in Europe.2,3 Policy decisions are still awaited in many countries, despite the unequivocal nature of the original NLST results.1 This is likely to be partly due to doubts fostered by the early publication of inconclusive results of a number of smaller trials in Europe.
New England Journal of Medicine , éditorial, 2019